| He Jing,Tang Xiaobin,Liu Yuanhao,Lin Xiaoyi,Kong Xiangquan.Progress in clinical trials of boron neutron capture therapy of head and neck cancers[J].Chinese Journal of Radiological Medicine and Protection,2020,40(8):642-647 |
| Progress in clinical trials of boron neutron capture therapy of head and neck cancers |
| Received:November 28, 2019 |
| DOI：10.3760/cma.j.issn.0254-5098.2020.08.012 |
| KeyWords:Boron neutron capture therapy Head and neck cancer Clinical trials Boron drug |
| FundProject:科技部国家重点研发计划项目（2017FYC0107700）；科技部国家国际科技合作专项（2016YFE0103600） |
| Author Name | Affiliation | E-mail | | He Jing | Department of Biology and Pharmacy, Nanjing Neuboron Medtech Ltd, Nanjing 211102, China | | | Tang Xiaobin | Department of Nuclear Science and Technology, Nanjing University of Aeronautics&Astronautics, Nanjing 211106, China | | | Liu Yuanhao | Department of Nuclear Science and Technology, Nanjing University of Aeronautics&Astronautics, Nanjing 211106, China | | | Lin Xiaoyi | Department of Radiation Oncology, Fujian Medical University Xiamen Humanity Hospital, Xiamen 361006, China | | | Kong Xiangquan | Department of Radiation Oncology, Fujian Medical University Xiamen Humanity Hospital, Xiamen 361006, China | kongxiangquan@haxm.org |
|
| Hits: 2733 |
| Download times: 1497 |
| Abstract:: |
| Boron neutron capture therapy(BNCT)is an advanced radiotherapy combined with targeted therapy and heavy ion therapy. BNCT is based on the nuclear reaction 10B (n, α) 7Li that occurs when boron-10 isotopes is irradiated with neutrons of the appropriate energy to produce high-energy recoiling 7Li nuclei and α particles. The released high linear energy transfer (LET) particles have path lengths of approximately one cell diameter (5-9 μm) and deposit most of their energy within the boron-containing tumor cells. BNCT has the advantages of precise tumor targeting, less damage to normal tissue and fewer irradiation fractionations (1-3 fractionations) than conventional radiotherapy (30 fractionation). The neutrons used in BNCT are produced by reactors or accelerators. The boron drugs used in clinical trials include BPA and BSH. In this paper, we review the clinical trial status and the significant progress of BNCT for head and neck tumors. The clinical data have approved the effectiveness of BNCT in the treatment of head and neck cancer. With the technical improvement of accelerator neutron source and the development of new boron drugs, BNCT will play a more important role in the field of clinical radiotherapy in the future. |
| HTML View Full Text View/Add Comment Download reader |
| Close |
|
|
|
